GyrB <i>in silico</i> mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin <i>in vitro</i> testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility

The zoliflodacin target GyrB was highly conserved among 27 151 global gonococcal isolates cultured in 1928-2021. The single zoliflodacin-resistant clinical isolate (0.0037%) was cultured from a male patient in Japan in 2000. Evidently, this strain has not clonally expanded nor has the gyrB zoliflodacin-resistance mutation disseminated through horizontal gene transfer to other strains. Phenotypic and genomic surveillance, including gyrB mutations, of zoliflodacin susceptibility are imperative.